STAAR Surgical Reports Q2 2026 Results; Strong China Growth Drives Profitability
STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5 million, up 111% year over year, driven by China. China sales were $52.3 million. Gross margin rose to 74.5%. Operating income was $10.1 million versus a $30.0 million loss a year earlier. Net income was $8.1 million ($0.16/share).
How this was made
The 30-second read
Why it matters
The profitability swing (operating income and net income turning positive) and strong China contribution can reset near-term expectations for revenue growth and margin trajectory. The tariff easing expectation tied to production shifting to Switzerland adds a forward-looking risk factor that may influence valuation.
Market read
Traders can use the reported financial inflection and China-led growth to update short-term positioning, while monitoring whether tariff and production-shift assumptions translate into sustained gross margin and operating leverage.
What to watch
The article does not quantify the magnitude/timing of tariff easing or provide full-year guidance, so traders may over-extrapolate the China contribution.
Background
STAAR Surgical is an ophthalmic device company; this report highlights a year-over-year rebound in Q2 2026 results, especially from China.
Ticker impact
STAAR reported Q2 2026 net sales of $93.5M, up 111% YoY, with operating income swinging to $10.1M from a prior-year loss.
Near-term bias higher as traders re-rate margins and China growth durability; watch for follow-through in subsequent quarters.
The article provides multiple concrete financial inflection points (sales, operating income, net income, EBITDA) plus a specific operational/tariff narrative that can affect expectations.
Market effects
Signals improving demand and margin leverage in ophthalmic surgical devices, potentially supporting sentiment for adjacent medtech names.
China outperformance is the key driver, which may influence how traders price China exposure in medtech/ophthalmology.
Tariff-production shift narrative (US to Switzerland) could affect cross-border cost assumptions for device makers with China sales.
Counterpoint
China growth may be partially cyclical or procedure-volume driven; without guidance numbers, durability of the margin rebound could be questioned.
Key entities
- companySTAAR Surgical
Reported Q2 2026 results with net sales up 111% YoY and operating income of $10.1M, driven by China demand.
